High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer

W. I. Bensinger, K. S. Schiffman, L. Holmberg, F. R. Appelbaum, Richard Maziarz, P. Montgomery, E. Ellis, S. Rivkin, P. Weiden, K. Lilleby, S. Rowley, S. Petersdorf, J. P. Klarnet, W. Nichols, A. Hertler, R. McCroskey, Ch Weaver, C. D. Buckner

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The purpose of this study was to determine the outcome of patients with metastatic breast cancer treated with high-dose busulfan (Bu), melphalan (Mel) and thiotepa (TT) followed by peripheral blood stem cell (PBSC) infusion. Fifty-one patients with chemotherapy refractory (n = 32) or responsive (n = 19) metastatic breast cancer received Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) followed by PBSC collected after chemotherapy and growth factor (n = 43) or growth factor alone (n = 8). The 100 day treatment-related mortality was 8% including one death from cytomegalovirus pneumonia, one from aspiration pneumonia and two from regimen-related toxicity (RRT). Seven of 28 refractory (25%) and 5/7 (71%) responsive patients with evaluable disease achieved a complete response of all measurable disease or all soft tissue disease with at least improvement in bone lesions (PR*). Fifteen of 51 patients (29%) are alive and progression-free a median of 423 days (range 353-934) after treatment, 5/32 (16%) with refractory disease and 10/19 (53%) with responsive disease. The probabilities of progression-free survival (PFS) at 1.5 years for the patients with refractory (N = 32) and responsive (n = 19) disease were 0.24 and 0.53, respectively. These preliminary data suggest that high-dose Bu/Mel/TT has significant activity in patients with advanced breast cancer and may be superior to some previously published regimens.

Original languageEnglish (US)
Pages (from-to)1183-1189
Number of pages7
JournalBone Marrow Transplantation
Volume19
Issue number12
StatePublished - Jun 2 1997
Externally publishedYes

Fingerprint

Thiotepa
Busulfan
Melphalan
Breast Neoplasms
Intercellular Signaling Peptides and Proteins
Therapeutics
Aspiration Pneumonia
Drug Therapy
Cytomegalovirus
Disease-Free Survival
Peripheral Blood Stem Cells
Pneumonia
Bone and Bones
Mortality

Keywords

  • Breast cancer
  • Busulfan
  • Melphalan
  • PBSC
  • Thiotepa

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Bensinger, W. I., Schiffman, K. S., Holmberg, L., Appelbaum, F. R., Maziarz, R., Montgomery, P., ... Buckner, C. D. (1997). High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplantation, 19(12), 1183-1189.

High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. / Bensinger, W. I.; Schiffman, K. S.; Holmberg, L.; Appelbaum, F. R.; Maziarz, Richard; Montgomery, P.; Ellis, E.; Rivkin, S.; Weiden, P.; Lilleby, K.; Rowley, S.; Petersdorf, S.; Klarnet, J. P.; Nichols, W.; Hertler, A.; McCroskey, R.; Weaver, Ch; Buckner, C. D.

In: Bone Marrow Transplantation, Vol. 19, No. 12, 02.06.1997, p. 1183-1189.

Research output: Contribution to journalArticle

Bensinger, WI, Schiffman, KS, Holmberg, L, Appelbaum, FR, Maziarz, R, Montgomery, P, Ellis, E, Rivkin, S, Weiden, P, Lilleby, K, Rowley, S, Petersdorf, S, Klarnet, JP, Nichols, W, Hertler, A, McCroskey, R, Weaver, C & Buckner, CD 1997, 'High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer', Bone Marrow Transplantation, vol. 19, no. 12, pp. 1183-1189.
Bensinger, W. I. ; Schiffman, K. S. ; Holmberg, L. ; Appelbaum, F. R. ; Maziarz, Richard ; Montgomery, P. ; Ellis, E. ; Rivkin, S. ; Weiden, P. ; Lilleby, K. ; Rowley, S. ; Petersdorf, S. ; Klarnet, J. P. ; Nichols, W. ; Hertler, A. ; McCroskey, R. ; Weaver, Ch ; Buckner, C. D. / High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. In: Bone Marrow Transplantation. 1997 ; Vol. 19, No. 12. pp. 1183-1189.
@article{a30958ffb94f48fe983e8c2b834c50c8,
title = "High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer",
abstract = "The purpose of this study was to determine the outcome of patients with metastatic breast cancer treated with high-dose busulfan (Bu), melphalan (Mel) and thiotepa (TT) followed by peripheral blood stem cell (PBSC) infusion. Fifty-one patients with chemotherapy refractory (n = 32) or responsive (n = 19) metastatic breast cancer received Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) followed by PBSC collected after chemotherapy and growth factor (n = 43) or growth factor alone (n = 8). The 100 day treatment-related mortality was 8{\%} including one death from cytomegalovirus pneumonia, one from aspiration pneumonia and two from regimen-related toxicity (RRT). Seven of 28 refractory (25{\%}) and 5/7 (71{\%}) responsive patients with evaluable disease achieved a complete response of all measurable disease or all soft tissue disease with at least improvement in bone lesions (PR*). Fifteen of 51 patients (29{\%}) are alive and progression-free a median of 423 days (range 353-934) after treatment, 5/32 (16{\%}) with refractory disease and 10/19 (53{\%}) with responsive disease. The probabilities of progression-free survival (PFS) at 1.5 years for the patients with refractory (N = 32) and responsive (n = 19) disease were 0.24 and 0.53, respectively. These preliminary data suggest that high-dose Bu/Mel/TT has significant activity in patients with advanced breast cancer and may be superior to some previously published regimens.",
keywords = "Breast cancer, Busulfan, Melphalan, PBSC, Thiotepa",
author = "Bensinger, {W. I.} and Schiffman, {K. S.} and L. Holmberg and Appelbaum, {F. R.} and Richard Maziarz and P. Montgomery and E. Ellis and S. Rivkin and P. Weiden and K. Lilleby and S. Rowley and S. Petersdorf and Klarnet, {J. P.} and W. Nichols and A. Hertler and R. McCroskey and Ch Weaver and Buckner, {C. D.}",
year = "1997",
month = "6",
day = "2",
language = "English (US)",
volume = "19",
pages = "1183--1189",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer

AU - Bensinger, W. I.

AU - Schiffman, K. S.

AU - Holmberg, L.

AU - Appelbaum, F. R.

AU - Maziarz, Richard

AU - Montgomery, P.

AU - Ellis, E.

AU - Rivkin, S.

AU - Weiden, P.

AU - Lilleby, K.

AU - Rowley, S.

AU - Petersdorf, S.

AU - Klarnet, J. P.

AU - Nichols, W.

AU - Hertler, A.

AU - McCroskey, R.

AU - Weaver, Ch

AU - Buckner, C. D.

PY - 1997/6/2

Y1 - 1997/6/2

N2 - The purpose of this study was to determine the outcome of patients with metastatic breast cancer treated with high-dose busulfan (Bu), melphalan (Mel) and thiotepa (TT) followed by peripheral blood stem cell (PBSC) infusion. Fifty-one patients with chemotherapy refractory (n = 32) or responsive (n = 19) metastatic breast cancer received Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) followed by PBSC collected after chemotherapy and growth factor (n = 43) or growth factor alone (n = 8). The 100 day treatment-related mortality was 8% including one death from cytomegalovirus pneumonia, one from aspiration pneumonia and two from regimen-related toxicity (RRT). Seven of 28 refractory (25%) and 5/7 (71%) responsive patients with evaluable disease achieved a complete response of all measurable disease or all soft tissue disease with at least improvement in bone lesions (PR*). Fifteen of 51 patients (29%) are alive and progression-free a median of 423 days (range 353-934) after treatment, 5/32 (16%) with refractory disease and 10/19 (53%) with responsive disease. The probabilities of progression-free survival (PFS) at 1.5 years for the patients with refractory (N = 32) and responsive (n = 19) disease were 0.24 and 0.53, respectively. These preliminary data suggest that high-dose Bu/Mel/TT has significant activity in patients with advanced breast cancer and may be superior to some previously published regimens.

AB - The purpose of this study was to determine the outcome of patients with metastatic breast cancer treated with high-dose busulfan (Bu), melphalan (Mel) and thiotepa (TT) followed by peripheral blood stem cell (PBSC) infusion. Fifty-one patients with chemotherapy refractory (n = 32) or responsive (n = 19) metastatic breast cancer received Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) followed by PBSC collected after chemotherapy and growth factor (n = 43) or growth factor alone (n = 8). The 100 day treatment-related mortality was 8% including one death from cytomegalovirus pneumonia, one from aspiration pneumonia and two from regimen-related toxicity (RRT). Seven of 28 refractory (25%) and 5/7 (71%) responsive patients with evaluable disease achieved a complete response of all measurable disease or all soft tissue disease with at least improvement in bone lesions (PR*). Fifteen of 51 patients (29%) are alive and progression-free a median of 423 days (range 353-934) after treatment, 5/32 (16%) with refractory disease and 10/19 (53%) with responsive disease. The probabilities of progression-free survival (PFS) at 1.5 years for the patients with refractory (N = 32) and responsive (n = 19) disease were 0.24 and 0.53, respectively. These preliminary data suggest that high-dose Bu/Mel/TT has significant activity in patients with advanced breast cancer and may be superior to some previously published regimens.

KW - Breast cancer

KW - Busulfan

KW - Melphalan

KW - PBSC

KW - Thiotepa

UR - http://www.scopus.com/inward/record.url?scp=0030800390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030800390&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 1183

EP - 1189

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -